ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 80 citations in OpenAlex.
- Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis.Annals of medicine · 2025Article
- Novel insights into the effect of sTIM-3 on NLRP3 inflammasome via interacting with ASC.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- The Ubiquitin-Proteasome System in Brain Disorders: Pathogenic Pathways, Post-Translational Tweaks, and Therapeutic Frontiers.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Review
- Polarization of THP-1-Derived Human M0 to M1 Macrophages Exposed to Flavored E-Liquids.Toxics · 2025Article
- The immune checkpoint pathophysiology of depression and chronic fatigue syndrome due to preeclampsia: focus on sCD80 and sCTLA-4.Acta neuropsychiatrica · 2025Article
- Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype.Frontiers in immunology · 2025Review
- Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.The Journal of experimental medicine · 2024Article
- Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies.Journal of experimental & clinical cancer research : CR · 2024Review
- sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence.Immunity & ageing : I & A · 2024Review
- Research progress of CD80 in the development of immunotherapy drugs.Frontiers in immunology · 2024Review
- Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming.Scientific reports · 2023Article
- A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Soluble CD80 oral delivery by recombinant Lactococcus suppresses tumor growth by enhancing antitumor immunity.Bioengineering & translational medicine · 2023Article
- Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity.Cancer science · 2023Article
- Targeting Cbl-b in cancer immunotherapy.Journal for immunotherapy of cancer · 2023Review
- Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.Frontiers in immunology · 2023Article
- Study of the clinicopathological features of soluble PD-L1 in lung cancer patients.Journal of rural medicine : JRM · 2023Article
- Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.World journal of gastroenterology · 2022Article
- Divergent roles of PD-L1 in immune regulation during ischemia-reperfusion injury.Frontiers in immunology · 2022Review
- Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.MedComm · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Many tumor cells escape anti-tumor immunity through their expression of programmed death ligand-1 (PDL1 or B7-H1), which interacts with T cell-expressed PD1 and results in T cell apoptosis. We previously reported that transfection of human tumor cells with a membrane-bound form of the human costimulatory molecule CD80 prevented PD1 binding and restored T cell activation. We now report that a membrane-bound form of murine CD80 similarly reduces PDL1-PD1-mediated suppression by mouse tumor cells and that a soluble protein consisting of the extracellular domains of human or mouse CD80 fused to the Fc domain of IgG1 (CD80-Fc) overcomes PDL1-mediated suppression by human and mouse tumor cells, respectively. T cell activation experiments with human and mouse tumor cells indicate that CD80-Fc facilitates T cell activation by binding to PDL1 to inhibit PDL1-PD1 interactions and by costimulating through CD28. CD80-Fc is more effective in preventing PD1-PDL1-mediated suppression and restoring T cell activation compared with treatment with mAb to either PD1 or PDL1. These studies identify CD80-Fc as an alternative and potentially more efficacious therapeutic agent for overcoming PDL1-induced immune suppression and facilitating tumor-specific immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.